![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
PREVIEW
The expanding pharmacopoeia for bipolar disorder has prompted both a rethinking of the term mood stabilizer and a succession of paradigm shifts in therapy. These changes have moved the therapeutic focus from lithium to anticonvulsant drugs and, most recently, to second-generation antipsychotics as foundational treatments of bipolar disorder. Here, Drs Goldberg and Citrome summarize the latest thinking about the relative roles of newer pharmacotherapies compared with older agents. They offer suggestions on how best to approach differential pharmacotherapy decisions for bipolar disorder, as informed by current evidence-based data.